Evidence for the clinical use of tumour markers

Ann Clin Biochem 2004;41:370-377
doi:10.1258/0004563041731529
© 2004 Association for Clinical Biochemistry

 

This Article
Right arrow

Full Text (PDF)

Right arrow
Alert me when this article is cited
Right arrow
Alert me if a correction is posted
Services
Right arrow
Email this article to a friend
Right arrow

Similar articles in this journal

Right arrow

Similar articles in Web of Science
Right arrow
Similar articles in PubMed
Right arrow
Alert me to new issues of the journal
Right arrow
Download to citation manager
Right arrow
Citing Articles
Right arrow
Citing Articles via HighWire
Right arrow
Citing Articles via Web of Science (16)


Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow
Articles by Duffy, M. J
Right arrow Search for Related Content
PubMed
Right arrow
PubMed Citation
Social Bookmarking

What’s this?

Review Articles


Michael J Duffy


Department of Nuclear Medicine, St Vincent’s University Hospital, Elm Park, Dublin 4, Ireland and Department of Surgery, Conway Institute of Biomolecular and Biomedical Research, University College Dublin and Dublin Molecular Medicine Institute, Dublin, Ireland

Testing for tumour markers should only be performed if it resultsin a better patient outcome, increased quality of life or reducedoverall cost of care. Ideally, the clinical value of a tumourmarker should be validated in a large prospective study or ameta-analysis of small-scale retrospective/prospective studies(i.e. a level 1 evidence study) prior to routine use. Markersthat have been validated in such a level 1 evidence study includecarcinoembryonic antigen in the surveillance of patients withdiagnosed colorectal cancer, alphafetoprotein, human chorionicgonadotrophin and lactate dehydrogenase for evaluating prognosisin patients non-seminomatous germ cell tumours, CA 125 for monitoringtherapy in patients with ovarian cancer, oestrogen receptorsfor predicting response to hormone therapy in breast cancer,HER-2 for predicting response to trastuzumab in patients withadvanced breast cancer and urokinase plasminogen activator/plasminogenactivator inhibitor type 1 for determining prognosis in breastcancer. Although currently in widespread use, the value of prostate-specificantigen in screening for prostate cancer has yet to be validatedin a large prospective randomized trial.


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What’s this?






This article has been cited by other articles:

Home page BMJHome page

C M Sturgeon, L C Lai, and M J Duffy
Serum tumour markers: how to order and interpret them
BMJ,

September 22, 2009;
339(sep22_1):
b3527 – b3527.

[Full Text]


Home page Ann Clin BiochemHome page

R. Franceschini, C. Trevisiol, R. Dittadi, and M. Gion
Tumour markers requesting pattern with regards to different organizational settings in Italy: a survey of hospital laboratories
Ann Clin Biochem,

July 1, 2009;
46(4):
316 – 321.

[Abstract]
[Full Text]
[PDF]